Anti-Acetyl MLL1 (KMT2A) (Lys 1130/1133)

Histone-lysine N-methyltransferase 2A (UniProt: Q03164; also known as EC: 2.1.1.43, Lysine N-methyltransferase 2A, ALL-1, CXXC-type zinc finger protein 7, Myeloid/lymphoid or mixed-lineage leukemia, Myeloid/lymphoid or mixed-lineage leukemia protein 1, MLL1, Trithorax-like protein, Zinc finger protein HRX) is encoded by the KMT2A (also known as ALL1, CXXC7, HRX, HTRX, MLL, MLL1, TRX1) gene (Gene ID: 4297) in human. It is expressed in heart, lung, and brain and in T- and B-lymphocytes and plays an essential role in early development and hematopoiesis. Proteolytic cleavage of MLL1 by Taspase 1 (TASP1) generates an N-terminal cleavage product of 320 kDa and a C-terminal product of 180 kDa. The catalytic subunit of the MLL1/MLL complex, a multiprotein complex that mediates both methylation of Lysine 4 of histone H3 (H3K4me) complex and acetylation of Lysine 16 of histone H4 (H4K16ac). In the MLL1/MLL complex, it specifically mediates H3K4me, a specific tag for epigenetic transcriptional activation. MLL1 displays weak methyltransferase activity by itself, and requires other component of the MLL1/MLL complex to obtain full methyltransferase activity. It does not exhibit any activity toward histone H3 phosphorylated on Threonine 3, and less activity toward H3 dimethylated on Arginine 8 or Lysine 9. However, it has higher activity toward H3 acetylated on Lysine 9. MLL1 is shown to be required for transcriptional activation of HOXA9 and it promotes PPP1R15A-induced apoptosis. MLL1 is reported to coordinate recruitment of CLOCK BMAL1 activator complexes to chromatin, an event associated with cyclic trimethylation of histone H3 Lysine 4 (H3K4) at circadian promoters. MLL1 is also reported to play a critical role in the control of circadian gene expression and is essential for the transcriptional activation mediated by the CLOCK-ARNTL/BMAL1 heterodimer. (Ref.: Aguilar-Arnal, L., et al. (2015). Nat. Struct. Mol. Biol. 22(4); 312-318).

This rabbit polyclonal antibody specifically detects human Histone-lysine N-methyltransferase 2A acetylated on lysine 1130 and 1133.

Epitope: unknown

KLH-cpnugated linear peptide corresponding to 12 amino acids surrounding acetylated lysines 1130 and 1133 from the N-terminal half of human Histone-lysine N-methyltransferase 2A.

Anti-Acetyl MLL1 (KMT2A) (Lys 1130/1133), Cat. No. ABE344, is a highly specific rabbit polyclonal antibody that targets Histone-lysine N-methyltransferase 2A (MLL1) acetylated on Lysine 1130/1133 and has been tested for use in Dot Blot, Peptide Inhibition Assay, and Western Blotting.

Research Category
Epigenetics & Nuclear Function

Western Blotting Analysis: A representative lot detected Acetyl MLL1 (KMT2A) (Lys 1130/1133) in Western Blotting applications (Aquilar-Arnal, L., et. al. (2015). Nat Struct Mol Biol. 22(4):312-8).

Peptide Inhibition Analysis: A representative lot was used with Acetylated peptide (Ag peptide) and Control peptide for peptide block analysis. (Courtesy of Dr. Lorena Aguilar-Arnal)

Evaluated by Dot Blot with Acetylated peptide (Ag peptide) and Control peptide.



Dot Blot Analysis: 1 µg/mL of this antibody detected Acetyl MLL1 (KMT2A) peptide acetylated on Lysine 1130/1133, but did not dectect the control peptide.

431.76 kDa calculated.

Affinity Purified

Format: Purified

Purified rabbit polyclonal antibody in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl, with 0.05% Sodium Azide without glycerol.

Stable for 1 year at 2-8°C from date of receipt.

Concentration: Please refer to lot specific datasheet.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.